News from amgen inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 27, 2015, 09:00 ET
Amgen Logo

Amgen Receives Positive CHMP Opinion For Use Of Vectibix® (panitumumab) As First-Line Treatment In Combination With FOLFIRI Chemotherapy For Advanced Colorectal Cancer

 Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...

Feb 26, 2015, 16:05 ET
Amgen Logo.

Amgen Announces The European Medicines Agency Acceptance Of Kyprolis® (Carfilzomib) Marketing Authorization Application For The Treatment Of Relapsed Multiple Myeloma

Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced that the European Medicines Agency (EMA) has accepted the...

Feb 25, 2015, 16:44 ET
Amgen Logo.

Amgen Announces Positive Results From Head-To-Head Study Comparing The Efficacy And Safety Of AMG 416 With Cinacalcet In Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Amgen (NASDAQ: AMGN) today announced results from the head-to-head Phase 3 study comparing AMG 416 with cinacalcet for the treatment of secondary...

Feb 25, 2015, 16:04 ET
Amgen Logo.

Amgen To Present At The Cowen And Company 35th Annual Health Care Conference

Amgen (NASDAQ: AMGN) will present at the Cowen and Company 35th Annual Health Care Conference at 2:50 p.m. ET on Monday, March 2, 2015, at the...

Feb 11, 2015, 16:22 ET
Amgen Logo.

Amgen Announces FDA Advisory Committees To Review Talimogene Laherparepvec For The Treatment Of Patients With Metastatic Melanoma

 Amgen (NASDAQ: AMGN) announced today that the Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) and the Oncologic Drugs Advisory...

Feb 03, 2015, 16:01 ET
Amgen Logo.

Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With Adalimumab In Patients With Moderate-To-Severe Rheumatoid Arthritis

Amgen (NASDAQ: AMGN) today announced a Phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira®...

Jan 29, 2015, 16:40 ET
Amgen Logo.

Amgen, The Familial Hypercholesterolemia Foundation And Stanford Medicine Launch FIND FH™ Initiative To Improve Diagnosis And Care For People With Familial Hypercholesterolemia

 Amgen (NASDAQ: AMGN), The Familial Hypercholesterolemia Foundation and Stanford Medicine today announced the launch of the FIND (FLAG,...

Jan 27, 2015, 16:02 ET
Amgen Logo.

Amgen Submits Applications In The US And Europe For Kyprolis® (carfilzomib) For The Treatment Of Relapsed Multiple Myeloma

 Amgen (NASDAQ:AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., today announced the submission of a supplemental New Drug Application...

Jan 27, 2015, 16:01 ET
Amgen Logo.

Amgen's 2014 Revenues Increased 7 Percent To $20.1 Billion And Adjusted Earnings Per Share (EPS) Increased 14 Percent To $8.70

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2014. Key results include: - For the fourth...

Jan 22, 2015, 16:01 ET
Amgen Logo.

Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results

 Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2014 financial results on Tuesday, Jan. 27, 2015,...

Jan 15, 2015, 16:01 ET
Amgen Logo.

Amgen Presents New Data Supporting First-Line Use Of Vectibix® (Panitumumab) In Combination With FOLFOX In Patients With Wild-Type RAS Metastatic Colorectal Cancer

Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 PEAK and Phase 3 PRIME studies that support the first-line use of Vectibix®...

Jan 12, 2015, 16:01 ET
Amgen Logo.

Amgen and MD Anderson Announce Agreement to Develop BiTE® Therapies for Myelodysplastic Syndrome

Amgen (NASDAQ: AMGN) and The University of Texas MD Anderson Cancer Center today announced a research collaborative agreement focusing on Amgen's...

Jan 08, 2015, 16:15 ET
Amgen Logo.

Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference

 Amgen (NASDAQ: AMGN) will present at the 33rd Annual J.P. Morgan Healthcare Conference at 9:30 a.m. PT on Tuesday, Jan. 13, 2015, at the...

Jan 05, 2015, 09:00 ET
Amgen Logo.

Amgen and Kite Pharma Announce Strategic Cancer Immunotherapy Collaboration to Advance the Application of Novel Chimeric Antigen Receptor (CAR) T Cell Therapies

 Amgen (NASDAQ:AMGN) and Kite Pharma (NASDAQ:KITE) announced today that the two companies have entered into a strategic research collaboration...

Dec 17, 2014, 17:45 ET
Amgen Logo.

Amgen Announces 30 Percent Increase In 2015 First Quarter Dividend

 Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $0.79 per share dividend for the first quarter of 2015. The...

Dec 11, 2014, 16:01 ET
Amgen Logo.

Amgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1™ Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis

Amgen (NASDAQ: AMGN) and AstraZeneca (NYSE: AZN) today announced that additional results from AMAGINE-1TM, a pivotal, multi-arm Phase 3 trial...

Dec 08, 2014, 21:00 ET
Amgen Logo.

Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia

 Amgen (NASDAQ: AMGN) today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO™ (blinatumomab) for the...

Dec 08, 2014, 16:20 ET
Amgen Logo.

New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA® (Pembrolizumab) For Advanced Melanoma

Amgen (NASDAQ: AMGN) today announced the initiation of a trial of talimogene laherparepvec, an investigational oncolytic immunotherapy, in...

Dec 08, 2014, 14:47 ET
Amgen Logo. (PRNewsFoto/Amgen)

Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma

 Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc., announced today results of the Phase 3 ASPIRE (CArfilzomib, Lenalidomide,...

Dec 08, 2014, 09:00 ET
Amgen Logo.

FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for XGEVA® (denosumab)...